Skip to main content
Erschienen in: Pathology & Oncology Research 1/2017

29.09.2016 | Original Article

Claudin-1 Protein Expression Is a Good Prognostic Factor in Non-Small Cell Lung Cancer, but only in Squamous Cell Carcinoma Cases

verfasst von: Judit Moldvay, Katalin Fábián, Márta Jäckel, Zsuzsanna Németh, Krisztina Bogos, József Furák, László Tiszlavicz, János Fillinger, Balázs Döme, Zsuzsa Schaff

Erschienen in: Pathology & Oncology Research | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

The aim of the study was to investigate the correlation between claudin (CLDN) protein expression and clinicopathological parameters as well as survival in histological subtypes of non-small cell lung cancer. Archived surgical resection specimens of 137 pathologic stage I primary bronchial cancers including 49 adenocarcinomas of non-lepidic variants (ADC), 46 adenocarcinomas of lepidic variants (L-ADC), and 42 squamous cell carcinomas (SCC) were examined. Immunohistochemistry (IHC) using antibodies against CLDN1,-2,-3,-4,-7 proteins as well as semiquantitative estimation (IHC scores 0–5) were performed. Claudin IHC scores of L-ADC differed significantly from ADC (CLDN1: p = 0.009, CLDN2: p = 0.005, CLDN3: p = 0.004, CLDN4: p = 0.001, CLDN7: p < 0.001, respectively) and SCC (CLDN1: p < 0.001, CLDN3: p < 0.001, CLDN7: p < 0.001, respectively). Highly significant CLDN3-CLDN4 parallel expression could be demonstrated in ADC and L-ADC (p < 0.001 in both), which was not observed in SCC (p = 0.131). ADC and SCC showed no correlation with smoking, whereas in case of L-ADC heavier smoking correlated with higher CLDN3 expression (p = 0.020). Regarding claudin expression and survival, in SCC significant correlation could be demonstrated between CLDN1 IHC positivity and better survival (p = 0.038). In NSCLC as a whole, high CLDN2 expression proved to be a better prognostic factor when compared with cases where CLDN2 IHC score was 0–1 vs. 2–5 (p = 0.009), however, when analyzed separately, none of the histological subgroups showed correlation between CLDN2 expression and overall survival. The claudin expression pattern was significantly different not only between the SCC–ADC and SCC–L-ADC but also between the L-ADC and ADC histological subgroups, which strongly underlines that L-ADC represents a distinct entity within the ADC group. CLDN1 overexpression is a good prognostic factor in NSCLC, but only in the SCC subgroup.
Literatur
1.
Zurück zum Zitat Yoshizawa A, Sumiyoshi S, Sonobe M, et al. (2013) Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol 8(1):52–61CrossRefPubMed Yoshizawa A, Sumiyoshi S, Sonobe M, et al. (2013) Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol 8(1):52–61CrossRefPubMed
2.
Zurück zum Zitat Travis WD, Brambilla E, Riely GJ (2013) New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol 31(8):992–1001CrossRefPubMed Travis WD, Brambilla E, Riely GJ (2013) New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol 31(8):992–1001CrossRefPubMed
3.
Zurück zum Zitat Sawada N, Murata M, Kikuchi K, et al. (2003) Tight junctions and human diseases. Med Electron Microsc 36:147–156CrossRefPubMed Sawada N, Murata M, Kikuchi K, et al. (2003) Tight junctions and human diseases. Med Electron Microsc 36:147–156CrossRefPubMed
4.
Zurück zum Zitat Chao YC, Pan SH, Yang SC, et al. (2009) Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma. Am J Respir Crit Care Med 179(2):123–133 Epub 2008 Sep 11CrossRefPubMed Chao YC, Pan SH, Yang SC, et al. (2009) Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma. Am J Respir Crit Care Med 179(2):123–133 Epub 2008 Sep 11CrossRefPubMed
5.
Zurück zum Zitat Merikallio H, Kaarteenaho R, Pääkkö P, et al. (2011) Impact of smoking on the expression of claudins in lung carcinoma. Eur J Cancer 47(4):620–630CrossRefPubMed Merikallio H, Kaarteenaho R, Pääkkö P, et al. (2011) Impact of smoking on the expression of claudins in lung carcinoma. Eur J Cancer 47(4):620–630CrossRefPubMed
6.
Zurück zum Zitat Zhang Z, Wang A, Sun B, et al. (2013) Expression of CLDN1 and CLDN10 in lung adenocarcinoma in situ and invasive lepidic predominant adenocarcinoma. J Cardiothorac Surg 8(1) Zhang Z, Wang A, Sun B, et al. (2013) Expression of CLDN1 and CLDN10 in lung adenocarcinoma in situ and invasive lepidic predominant adenocarcinoma. J Cardiothorac Surg 8(1)
7.
Zurück zum Zitat Zhang ZF1, Pei BX, Wang AL, et al. Expressions of CLDN1 and insulin-like growth factor 2 are associated with poor prognosis in stage N2 non-small cell lung cancer. Chin Med J. 2013; 126(19):3668–74. Zhang ZF1, Pei BX, Wang AL, et al. Expressions of CLDN1 and insulin-like growth factor 2 are associated with poor prognosis in stage N2 non-small cell lung cancer. Chin Med J. 2013; 126(19):3668–74.
8.
Zurück zum Zitat Yamamoto T, Oshima T, Yoshihara K, et al. (2010) Reduced expression of claudin-7 is associated with poor outcome in non-small cell lung cancer. Oncol Lett 1(3):501–505PubMedPubMedCentral Yamamoto T, Oshima T, Yoshihara K, et al. (2010) Reduced expression of claudin-7 is associated with poor outcome in non-small cell lung cancer. Oncol Lett 1(3):501–505PubMedPubMedCentral
9.
Zurück zum Zitat Travis WD, Brambilla E, Noguchi M, et al. (2011) International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6:244–285CrossRefPubMedPubMedCentral Travis WD, Brambilla E, Noguchi M, et al. (2011) International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6:244–285CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Moldvay J, Jäckel M, Páska C, Soltész I, Schaff Z, Kiss A (2007) Distinct claudin expression profile in histologic subtypes of lung cancer. Lung Cancer 57(2):159–167 Epub 2007 Apr 6CrossRefPubMed Moldvay J, Jäckel M, Páska C, Soltész I, Schaff Z, Kiss A (2007) Distinct claudin expression profile in histologic subtypes of lung cancer. Lung Cancer 57(2):159–167 Epub 2007 Apr 6CrossRefPubMed
11.
Zurück zum Zitat Kominsky SL, Argani P, Korz D, et al. (2003) Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene 22:2021–2033CrossRefPubMed Kominsky SL, Argani P, Korz D, et al. (2003) Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene 22:2021–2033CrossRefPubMed
12.
13.
Zurück zum Zitat Szasz AM, Tokes AM, Micsinai M, et al. (2011) Prognostic significance of claudin expression changes in breast cancer with regional lymph node metastasis. Clin Exp Metastasis 28(1):55–63 Epub 2010 Oct 21CrossRefPubMed Szasz AM, Tokes AM, Micsinai M, et al. (2011) Prognostic significance of claudin expression changes in breast cancer with regional lymph node metastasis. Clin Exp Metastasis 28(1):55–63 Epub 2010 Oct 21CrossRefPubMed
14.
Zurück zum Zitat Kolokytha P, Yiannou P, Keramopoulos D, et al. (2014) Claudin-3 and claudin-4: distinct prognostic significance in triple-negative and luminal breast cancer. Appl Immunohistochem Mol Morphol 22(2):125–131CrossRefPubMed Kolokytha P, Yiannou P, Keramopoulos D, et al. (2014) Claudin-3 and claudin-4: distinct prognostic significance in triple-negative and luminal breast cancer. Appl Immunohistochem Mol Morphol 22(2):125–131CrossRefPubMed
15.
Zurück zum Zitat Fritzsche FR, Oelrich B, Johannsen M, et al. (2008) Claudin-1 protein expression is a prognostic marker of patient survival in renal cell carcinomas. Clin Cancer Res 14(21):7035–7042CrossRefPubMed Fritzsche FR, Oelrich B, Johannsen M, et al. (2008) Claudin-1 protein expression is a prognostic marker of patient survival in renal cell carcinomas. Clin Cancer Res 14(21):7035–7042CrossRefPubMed
16.
Zurück zum Zitat Resnick MB, Konkin T, Routhier J, et al. (2005) Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray study. Mod Pathol 18:511–518CrossRefPubMed Resnick MB, Konkin T, Routhier J, et al. (2005) Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray study. Mod Pathol 18:511–518CrossRefPubMed
18.
Zurück zum Zitat Hsueh C, Chang YS, Tseng NM, et al. (2010) Expression pattern and prognostic significance of claudins 1, 4, and 7 in nasopharyngeal carcinoma. Hum Pathol 41(7):944–950 Epub 2010 Mar 23CrossRefPubMed Hsueh C, Chang YS, Tseng NM, et al. (2010) Expression pattern and prognostic significance of claudins 1, 4, and 7 in nasopharyngeal carcinoma. Hum Pathol 41(7):944–950 Epub 2010 Mar 23CrossRefPubMed
19.
Zurück zum Zitat Melchers LJ, Bruine de Bruin L, Schnell U, et al. (2013) Lack of claudin-7 is a strong predictor of regional recurrence in oral and oropharyngeal squamous cell carcinoma. Oral Oncol 49(10):998–1005CrossRefPubMed Melchers LJ, Bruine de Bruin L, Schnell U, et al. (2013) Lack of claudin-7 is a strong predictor of regional recurrence in oral and oropharyngeal squamous cell carcinoma. Oral Oncol 49(10):998–1005CrossRefPubMed
21.
Zurück zum Zitat Szász AM, Nyirády P, Majoros A, et al. (2010) Beta-catenin expression and claudin expression pattern as prognostic factors of prostatic cancer progression. BJU Int 105(5):716–722 Epub 2009 Oct 10CrossRefPubMed Szász AM, Nyirády P, Majoros A, et al. (2010) Beta-catenin expression and claudin expression pattern as prognostic factors of prostatic cancer progression. BJU Int 105(5):716–722 Epub 2009 Oct 10CrossRefPubMed
Metadaten
Titel
Claudin-1 Protein Expression Is a Good Prognostic Factor in Non-Small Cell Lung Cancer, but only in Squamous Cell Carcinoma Cases
verfasst von
Judit Moldvay
Katalin Fábián
Márta Jäckel
Zsuzsanna Németh
Krisztina Bogos
József Furák
László Tiszlavicz
János Fillinger
Balázs Döme
Zsuzsa Schaff
Publikationsdatum
29.09.2016
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 1/2017
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-016-0115-0

Weitere Artikel der Ausgabe 1/2017

Pathology & Oncology Research 1/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.